



Clinical Commissioning Policy Proposition:

**The use of Stereotactic Ablative
Radiotherapy (SABR) in the treatment of
Oligometastatic disease.**

Reference: NHS England B01X28

OFFICIAL

Clinical Commissioning Policy Proposition: The use of Stereotactic Ablative Radiotherapy (SABR) in the treatment of Oligometastatic disease

Reference: NHS England B01X28 (linked to B01/P/a, 2013)

First published:

Prepared by NHS England Specialised Services Clinical Reference Group for Radiotherapy

Classification: OFFICIAL

The National Health Service Commissioning Board was established on 1 October 2012 as an executive non-departmental public body. Since 1 April 2013, the National Health Service Commissioning Board has used the name NHS England for operational purposes.

Published by NHS England, in electronic format only.

Draft for public consultation

Contents

Contents	3
1 Executive Summary	4
Policy Statement	4
Equality Statement.....	4
Plain Language Summary	4
2 Introduction	5
3 Proposed Intervention and Clinical Indication	5
4 Definitions	5
5 Aims and Objectives	6
6 Epidemiology and Needs Assessment.....	7
7. Evidence Base.....	11
8. Documents That Have Informed This Policy Proposition.....	11
9 Date of Review	12

Draft for public consultation

1 Executive Summary

Policy Statement

NHS England proposes to not routinely commission Stereotactic Ablative Radiotherapy in the treatment of oligometastatic disease.

In creating this policy proposition NHS England has reviewed a number of clinical conditions and the options for treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

Equality Statement

NHS England has a duty to have regard to the need to reduce health inequalities in access to health services and health outcomes achieved as enshrined in the Health and Social Care Act 2012. NHS England is committed to fulfilling this duty as to equality of access and to avoiding unlawful discrimination on the grounds of age, gender, disability (including learning disability), gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, gender or sexual orientation. In carrying out its functions, NHS England will have due regard to the different needs of protected equality groups, in line with the Equality Act 2010. This document is compliant with the NHS Constitution and the Human Rights Act 1998. This applies to all activities for which NHS England is responsible, including policy development, review and implementation.

Plain Language Summary

The policy proposition aims to confirm NHS England's commissioning approach to the use of Stereotactic Ablative Radiotherapy (SABR) in the treatment of oligometastatic disease.

Stereotactic body radiotherapy refers to the use of highly targeted radiation therapy to structures outside the brain and skull.

2 Introduction

This document describes the evidence that has been considered by NHS England in formulating a proposal to not routinely commission Stereotactic Ablative Radiotherapy in the treatment of oligometastatic disease.

For the purpose of consultation NHS England invites views on the evidence and other information that has been taken into account as described in this policy proposition.

A final decision as to whether NHS England will continue to routinely commission SABR in the treatment of oligometastatic disease is planned to be made by NHS England by May 2016 following a recommendation from the Clinical Priorities Advisory Group.

3 Proposed Intervention and Clinical Indication

For the purpose of this policy SABR refers to hypo-fractionated treatment of not more than 8 fractions.

Commissioning arrangements for fractionated treatments utilising a larger number of fractions are beyond the remit of this policy.

This policy concerns the use of SABR in the treatment of oligometastatic disease.

4 Definitions

Stereotactic body radiotherapy (SABR) refers to the precise irradiation of an image defined extra cranial lesion and is associated with the use of a high radiation dose delivered in a small number of fractions. The technique requires specialist positioning equipment and imaging to confirm correct targeting. It allows sparing of the surrounding healthy normal tissues.

Stereotactic radiation therapy has been used for benign and malignant lesions in the brain for many years. Stereotactic radiosurgery (SRS) is a single fraction of stereotactic directed radiation of a limited volume in the brain or other structure of the skull base, whereas stereotactic radiotherapy (SRT) has been defined as a fractionated stereotactic directed radiation of a limited volume in the brain.

Stereotactic Ablative radiotherapy (SABR) refers to the use of stereotactically directed radiation therapy to structures outside the brain and skull.

Extra-cranial malignant disease

Extra-cranial malignant disease is a catch all term for all malignancies excluding cerebral metastases, which is the subject of a separate policy.

Oligometastatic disease

If not treated in time, malignant tumours often spread by means of distant metastases. In 1995, Hellman and Weichselbaum coined the term oligometastatic disease, hypothesising that some patients enter a transitional state between localised disease and widespread, incurable metastatic spread. During this period, patients have a limited number of clinically detectable metastases, removal or ablation of which may prolong survival or even be curative. An alternative hypothesis is that patients with apparently oligometastatic disease often also harbour many occult deposits which will progress and limit life expectancy, whatever local treatments are used for the manifest disease.

Neither of these views is universally accurate. There are patients in both these categories, though it is difficult to separate them prospectively. Oncologists are more likely to treat metastases with curative intent in patients whose primary tumour has been treated with apparent success, whose metastases appear small and few in number and whose prognosis would be materially improved by treating them. Other relevant factors are the patient's age, comorbidity and performance status.

Treatments for metastases include surgical excision, radio-frequency or microwave ablation, locally delivered chemotherapy and external beam radiotherapy. Another treatment option is SABR.

5 Aims and Objectives

This policy proposition considered:

Whether there is sufficient robust evidence of clinical and cost- effectiveness and safety to support the use of SABR in the treatment of patients with oligometastatic

disease.

The objectives were:

To identify whether the evidence is sufficiently robust and what criteria should be used to identify suitable patients to be considered for SABR.

6 Epidemiology and Needs Assessment

Four systematic reviews were identified in relation to these oligometastatic disease:

- Florescu and Thariat (2014) systematically reviewed published evidence about the treatment of metastatic head and neck cancer (search date 2012). The review contained only limited information on how it was carried out.

The authors found 12 studies of the use of SABR, with a variety of durations, treatment regimens, inclusion and exclusion criteria and follow-up. This made it impossible to meta-analyse the results or even to draw general conclusions. None of the studies was randomised. All but two were uncontrolled, and so provide no information on the benefits for patients of SABR versus other treatment options.

Of the controlled studies, the first evaluated pulmonary metastasectomy, with SABR as a treatment for participants less suitable for surgery (Widder et al 2013). Survival was similar after the two treatments. The other controlled study included participants with brain metastases who received surgery, whole brain radiotherapy, surgery plus whole brain radiotherapy, radiosurgery (i.e. SABR) or supportive care (Maclean et al 2013). No conclusive results about the effectiveness of SABR emerged from this study.

Florescu and Thariat's review provides no reliable information on the outcomes of SABR versus other treatments for metastatic head and neck cancers.

- Ashworth et al (2013) published a systematic review of the treatment of oligometastatic non-small cell lung cancer (search date 2012). The

authors included studies of people with tumours of that histological type and fewer than six metastases. Studies were included whether or not the primary was controlled. The review was rigorously carried out and thoroughly reported.

Ashworth et al found no randomised trials, and none of the studies was apparently controlled. They found five studies of SABR, but do not report details of the regimes or the results according to the mode of treatment. They do report a wide range of outcomes among the studies of all interventions, with five-year survival ranging from 8.3 to 86 percent. Half of the participants in the studies progressed within a year.

- Gunjar et al (2014) reviewed systematically the treatment of tumours metastatic to the adrenal gland (search date 2012). They included studies regardless of the extent of control of the primary or the number of metastases.

Gunjar et al found nine published studies of SABR for adrenal metastases, reporting 178 participants. All studies were uncontrolled, and there were a wide range of total radiation doses (from 10 to 60 Gy) delivered in one to eighteen fractions. Sixty-eight percent of patients had lung cancer.

The authors apparently carried out no tests for heterogeneity but nevertheless pooled the results. At two years, the rate of local control was 63%, and overall survival was 19%. The results from the studies of adrenalectomy were better – 84% and 46% respectively. Although the studies of the two treatments were not comparable, Gunjar et al concluded that “surgery appears to be the most reasonable option, given the large body of retrospective data ... and the apparently acceptable complication rates.”

The heterogeneity of the studies in Gunjar et al’s review casts doubt on the appropriateness of pooling the studies, but their results provide no basis for a conclusion that SABR is a better alternative to surgery.

- Siva et al (2010) carried out a similar review of the treatment of pulmonary metastases (search date 2009). The authors included six studies of unfractionated treatment reporting a total of 148 participants, and 13 studies of fractionated treatment, in 334 people. All studies were uncontrolled, and they varied widely in dosage regimens, lesion size, maximum number of metastases, duration of follow-up and reported outcomes.

As undeterred by this heterogeneity as Gunjar et al, Siva et al pooled the results. The unfractionated studies reported a weighted two-year local control rate of 79% (range 48% to 91%) and a two-year overall survival rate of 50% (range 33% to 73%). The corresponding figures for fractionated treatment are 78% (67% to 96%) and 54% (33% to 89%).

Again, these pooled results must be treated with caution because of the studies' heterogeneity.

One randomised controlled trial was identified. Lim et al (2014) randomised 105 people with non-small cell lung cancer and cerebral metastases to either stereotactic radiosurgery followed by chemotherapy or chemotherapy alone. Overall survival and progression-free survival for cranial disease were similar in the two groups.

33 uncontrolled studies of SABR for oligometastatic disease were identified. The review for this policy included those reporting at least 75 participants; including further uncontrolled studies would have not provided any further information on the effectiveness of SABR relative to other treatments. There were seven such studies:

- Comito et al (2014) studied 82 people with one to three colorectal metastases in the liver or lung. Median overall survival was 32 months, with 43% of participants surviving to 3 years. Rates of local control were higher than overall survival, suggesting that occult metastases were often responsible for participants' deaths.

- Fumagalli et al (2012) reported a series of 90 heavily pre-treated participants with five or fewer hepatic or pulmonary metastases.[10] Most had a single metastasis. Seventy-two per cent of tumours showed a response to SABR, and local control was maintained at two years in two-thirds of participants. However, the effect on longevity was modest: median disease-free survival was less than seven months and only one in ten participants was alive and disease-free at two years.
- Jereczek-Fossa et al's (2013) study included 95 people with up to five metastases in a wider range of organs, mainly brain, bone and lymph nodes. Thirty-one percent of lesions were primary tumours. Despite a bias in the ascertainment of response rates likely to inflate them, only 46% of lesions responded to SABR. Over three years, more than four out of five patients progressed despite treatment, and more than two-thirds died.
- Navarra et al (2014) reported 76 participants treated for no more than five lung metastases. These authors used higher doses of radiation than Jereczek-Fossa et al, and reported better survival. Sixty per cent of lesions showed a complete response to treatment, and a further 29% had a partial response. Despite this, median survival was only 20 months. The reported rates of local control (89%), progression-free survival (70%) and overall survival (73%) were the same at two and at three years. It is likely that some patients with metastatic cancer would experience loss of local control, progression or death in the third year after treatment. Perhaps these results were based on small numbers of potentially unrepresentative longer-term survivors, and may therefore be statistically unstable and less reliable.
- Milano et al's (2012) cohort had a high proportion of women with metastatic breast cancer. All the participants had a maximum of five metastases. The results for the breast cancer participants were better, with 47% survival to six years, compared with only 9% for the other

primary sites. Milano et al investigated several other potentially important prognostic factors but none significantly affected outcomes.

- Milano et al (2010) published a separate study of 77 patients from the above cohort whose metastases were confined to a single organ. After median follow-up of 23 months, 47 (61%) had died.

Wang et al (2012) reported results from 149 people with mechanically stable, non-cord-compressing spinal metastases.[15] The number reporting no pain from bone metastases increased from 26% before treatment to 54% six months after treatment.

7. Evidence Base

The evidence regarding the effectiveness and safety of SABR for treating patients with oligometastatic disease has been used as a basis for this commissioning policy. The evidence base indicates that there is insufficient evidence to routinely commission SABR for this cohort of patients.

This policy will replace the current published clinical commissioning policy statement on this topic.

NHS England commissioned an evidence review (Solutions for Public Health, 2015) in relation to the clinical indication outlined in this policy.

8. Documents That Have Informed This Policy Proposition

National Radiotherapy Implementation Group Report. Stereotactic Body Radiotherapy Guidelines for Commissioners, Providers and Clinicians in England 2011. Available from:

[http://www.ncat.nhs.uk/sites/default/files/NRIG%20SBRT%20Final%20June%202011.](http://www.ncat.nhs.uk/sites/default/files/NRIG%20SBRT%20Final%20June%202011.pdf)

[pdf](#). Accessed September 2012.

National Radiotherapy Implementation Group Report. Stereotactic Body Radiotherapy Clinical review of the evidence for SBRT 2011.

Yorkshire and the Humber commissioning policy
Stereotactic radiosurgery/radiotherapy.

9 Date of Review

This document will lapse upon publication by NHS England of a clinical commissioning policy for the proposed intervention that confirms whether it is routinely or non-routinely commissioned (expected by May 2016).

References

Weichselbaum RR, Hellman S. Oligometastases revisited. *Nat Rev Clin Oncol*. 2011; 8(6): 378-82.

Aitken KL, Hawkins MA. Stereotactic Body Radiotherapy for Liver Metastases. *Clin Oncol (R Coll Radiol)*. 2015.

Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, et al. Stereotactic body radiotherapy for oligometastases. *Lancet Oncol*. 2013; 14(1): e28-37.

Lo SS, Moffatt-Bruce SD, Dawson LA, Schwarz RE, Teh BS, Mayr NA, et al. The role of local therapy in the management of lung and liver oligometastases. *Nat Rev Clin Oncol*. 2011.

Hoyer M, Swaminath A, Bydder S, Lock M, Mendez Romero A, Kavanagh B, et al. Radiotherapy for liver metastases: a review of evidence. *Int J Radiat Oncol Biol Phys*. 2012; 82(3): 1047-57.

Scheffer TE, Kavanagh BD. Radiation therapy for liver metastases. *Semin Radiat Oncol*. 2011; 21(4): 264-70.

Dhakal S, Corbin KS, Milano MT, Philip A, Sahasrabudhe D, Jones C, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. *Int J Radiat Oncol Biol Phys.* 2012; 82(2): 940-5.

Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, et al. Stereotactic body radiation therapy for lung metastases. *Lung Cancer.* 2012; 75(1): 77-81.

Zhang Y, Xiao JP, Zhang HZ, Yin WB, Hu YM, Song YX, et al. Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution. *Chin Med J (Engl).* 2011; 124(24): 4132-7.

Vautravers-Dewas C, Dewas S, Bonodeau F, Adenis A, Lacornerie T, Penel N, et al. Image-Guided Robotic Stereotactic Body Radiation Therapy for Liver Metastases: Is There a Dose Response Relationship? *Int J Radiat Oncol Biol Phys.* 2011.

Carey Sampson M, Katz A, Constone LS. Stereotactic body radiation therapy for extracranial oligometastases: does the sword have a double edge? *Semin Radiat Oncol.* 2006; 16(2): 67-76.

Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. *Semin Radiat Oncol.* 2008; 18(4): 215-22.

Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. *Med Phys.* 2010; 37(8): 4078-101.

Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. *Cancer.* 2008; 112(3): 650-8.

Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report

of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. *Cancer*. 2011.

Kang JK, Kim MS, Kim JH, Yoo SY, Cho CK, Yang KM, et al. Oligometastases confined one organ from colorectal cancer treated by SBRT. *Clin Exp Metastasis*. 2010; 27(4): 273-8.

Inoue T, Katoh N, Aoyama H, Onimaru R, Taguchi H, Onodera S, et al. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions. *Jpn J Clin Oncol*. 2010; 40(8): 788-94.

Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. *Radiat Oncol*. 2011; 6: 34.

Bae SH, Kim MS, Cho CK, Kang JK, Kang HJ, Kim YH, et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. *J Surg Oncol*. 2012.

Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, et al. Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate Cancer. *Int J Radiat Oncol Biol Phys*. 2011.

Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. *Acta Oncol*. 2006; 45(7): 823-30.

Wersall PJ, Blomgren H, Lax I, Kalkner KM, Linder C, Lundell G, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. *Radiother Oncol*. 2005; 77(1): 88-95.

Svedman C, Sandstrom P, Pisa P, Blomgren H, Lax I, Kalkner KM, et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. *Acta Oncol*. 2006; 45(7): 870-5.

Nuyttens JJ, Prevost JB, Van der Voort van Zijp NC, Hoogeman M, Levendag PC. Curative stereotactic robotic radiotherapy treatment for extracranial, extrapulmonary, extrahepatic, and extraspinal tumors: technique, early results, and toxicity. *Technol Cancer Res Treat*. 2007; 6(6): 605-10.

Greco C, Zelefsky MJ, Lovelock M, Fuks Z, Hunt M, Rosenzweig K, et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. *Int J Radiat Oncol Biol Phys*. 2011; 79(4): 1151-7.

Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. *Urol Oncol*. 2011.

Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gning I, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. *Lancet Oncol*. 2012.

Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, et al. *Int J Radiat Oncol Biol Phys*. 2008; 71(2): 484-90.

Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. *Spine (Phila Pa 1976)*. 2007; 32(2): 193-9.

Zelefsky MJ, Greco C, Motzer R, Magsanoc JM, Pei X, Lovelock M, et al. Tumor Control Outcomes After Hypofractionated and Single-Dose Stereotactic Image-Guided Intensity-Modulated Radiotherapy for Extracranial Metastases From Renal Cell Carcinoma. *Int J Radiat Oncol Biol Phys*. 2011.

Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. *Int J Radiat Oncol Biol Phys*. 2010; 76(4): 1185-92.

Draft for public consultation